An enhanced Lactobacillus reuteri biofilm formulation that increases protection against experimental necrotizing enterocolitis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 315, Issue 3, 2018, Pages G408-G419

  Olson, Jacob K ^a   Navarro, Jason B ^b   Allen, Jacob M ^b   McCulloh, Christopher J ^a   Mashburn Warren, Lauren ^b   Wang, Yijie ^a   Varaljay, Vanessa A ^b   Bailey, Michael T ^b   Goodman, Steven D ^b   Besner, Gail E ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Biofilm; Lactobacillus reuteri; Necrotizing enterocolitis; Probiotics

Indexed keywords

MALTOSE; PROBIOTIC AGENT; SUCROSE; DEXTRAN; DEXTRANOMER; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BIOFILM; CONTROL; CONTROLLED STUDY; GTFW GENE; INOCULATION; INTESTINE FLORA; LACTOBACILLUS REUTERI; NECROTIZING ENTEROCOLITIS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; INFLAMMATION; INTESTINE; MICROBIOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; BIOFILMS; DEXTRANS; DRUG DELIVERY SYSTEMS; ENTEROCOLITIS, NECROTIZING; INFLAMMATION; INTESTINES; LACTOBACILLUS REUTERI; MICROSPHERES; PROBIOTICS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 85053673869     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00078.2018     Document Type: Article

References (71)

1. Abrahamsson TR, Jakobsson T, Böttcher MF, Fredrikson M, Jen-malm MC, Björkstén B, Oldaeus G. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 119: 1174–1180, 2007. doi:10.1016/j.jaci.2007.01. 007.
2. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, von Wright A. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 65: 351–354, 1999.
3. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev (4): CD005496, 2014. doi:10.1002/14651858.CD005496.pub4.
4. Ambalam P, Raman M, Purama RK, Doble M. Probiotics, prebiotics and colorectal cancer prevention. Best Pract Res Clin Gastroenterol 30: 119–131, 2016. doi:10.1016/j.bpg.2016.02.009.
5. Arciero J, Bard Ermentrout G, Siggers R, Afrazi A, Hackam D, Vodovotz Y, Rubin J. Modeling the interactions of bacteria and Toll-like receptor-mediated inflammation in necrotizing enterocolitis. J Theor Biol 321: 83–99, 2013. doi:10.1016/j.jtbi.2012.12.002.
6. Barlow B, Santulli TV. Importance of multiple episodes of hypoxia or cold stress on the development of enterocolitis in an animal model. Surgery 77: 687–690, 1975.
7. Barlow B, Santulli TV, Heird WC, Pitt J, Blanc WA, Schullinger JN. An experimental study of acute neonatal enterocolitis–the importance of breast milk. J Pediatr Surg 9: 587–595, 1974. doi:10.1016/0022-3468(74)90093-1.
8. Bergmann KR, Liu SX, Tian R, Kushnir A, Turner JR, Li HL, Chou PM, Weber CR, De Plaen IG. Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. Am J Pathol 182: 1595–1606, 2013. doi:10.1016/j.ajpath. 2013.01.013.
9. Berrington JE, Stewart CJ, Embleton ND, Cummings SP. Gut microbiota in preterm infants: assessment and relevance to health and disease. Arch Dis Child Fetal Neonatal Ed 98: F286–F290, 2013. doi:10.1136/archdischild-2012-302134.
10. Caplan MS, Hedlund E, Adler L, Hsueh W. Role of asphyxia and feeding in a neonatal rat model of necrotizing enterocolitis. Pediatr Pathol 14: 1017–1028, 1994. doi:10.3109/15513819409037698.
11. Cassir N, Simeoni U, La Scola B. Gut microbiota and the pathogenesis of necrotizing enterocolitis in preterm neonates. Future Microbiol 11: 273–292, 2016. doi:10.2217/fmb.15.136.
12. Claud EC, Keegan KP, Brulc JM, Lu L, Bartels D, Glass E, Chang EB, Meyer F, Antonopoulos DA. Bacterial community structure and functional contributions to emergence of health or necrotizing enterocolitis in preterm infants. Microbiome 1: 20, 2013. doi:10.1186/2049-2618-1-20.
13. De Groote MA, Frank DN, Dowell E, Glode MP, Pace NR. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 24: 278–280, 2005. doi:10. 1097/01.inf.0000154588.79356.e6.
14. de Man JC, Rogosa M, Sharpe ME. A medium for the cultivation of Lactobacilli. J Appl Microbiol 23: 130–135, 1960. doi:10.1111/j.1365-2672.1960.tb00188.x.
15. Dicksved J, Schreiber O, Willing B, Petersson J, Rang S, Phillipson M, Holm L, Roos S. Lactobacillus reuteri maintains a functional mucosal barrier during DSS treatment despite mucus layer dysfunction. PLoS One 7: e46399, 2012. doi:10.1371/journal.pone.0046399.
16. Ding WK, Shah NP. Acid, bile, and heat tolerance of free and microen-capsulated probiotic bacteria. J Food Sci 72: M446–M450, 2007. doi:10. 1111/j.1750-3841.2007.00565.x.
17. Good M, Sodhi CP, Ozolek JA, Buck RH, Goehring KC, Thomas DL, Vikram A, Bibby K, Morowitz MJ, Firek B, Lu P, Hackam DJ. Lactobacillus rhamnosus HN001 decreases the severity of necrotizing enterocolitis in neonatal mice and preterm piglets: evidence in mice for a role of TLR9. Am J Physiol Gastrointest Liver Physiol 306: G1021– G1032, 2014. doi:10.1152/ajpgi.00452.2013.
18. Grishin A, Papillon S, Bell B, Wang J, Ford HR. The role of the intestinal microbiota in the pathogenesis of necrotizing enterocolitis. Semin Pediatr Surg 22: 69–75, 2013. doi:10.1053/j.sempedsurg.2013.01. 002.
19. Groer MW, Luciano AA, Dishaw LJ, Ashmeade TL, Miller E, Gilbert JA. Development of the preterm infant gut microbiome: a research priority. Microbiome 2: 38, 2014. doi:10.1186/2049-2618-2-38.
20. Grönlund MM, Lehtonen OP, Eerola E, Kero P. Fecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after cesarean delivery. J Pediatr Gastroenterol Nutr 28: 19–25, 1999. doi:10.1097/00005176-199901000-00007.
21. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, Krabshuis J, Lemair T, Kaufmann P, de Paula JA, Fedorak R, Shanahan F, Sanders ME, Szajewska H, Ramakrishna BS, Kara-kan T, Kim N; World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 46: 468–481, 2012. doi:10.1097/MCG.0b013e3182549092.
22. Gutierrez-Castrellon P, Lopez-Velazquez G, Diaz-Garcia L, Jimenez-Gutierrez C, Mancilla-Ramirez J, Estevez-Jimenez J, Parra M. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics 133: e904–e909, 2014. doi:10.1542/peds.2013-0652.
23. Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, Wagendorp AA, Klijn N, Bindels JG, Welling GW. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr 30: 61–67, 2000. doi:10.1097/00005176-200001000-00019.
24. Henry MC, Moss RL. Necrotizing enterocolitis. Annu Rev Med 60: 111–124, 2009. doi:10.1146/annurev.med.60.050207.092824.
25. Hoy SM. Dextranomer in stabilized sodium hyaluronate (Solesta®): in adults with faecal incontinence. Drugs 72: 1671–1678, 2012. doi:10.2165/11209030-000000000-00000.
26. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 3: 197–202, 1999. doi:10.1016/S1201-9712(99)90024-3.
27. Hunter C, Dimaguila MA, Gal P, Wimmer JE Jr, Ransom JL, Carlos RQ, Smith M, Davanzo CC. Effect of routine probiotic, Lactobacillus reuteri DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight < 1000 grams: a sequential analysis. BMC Pediatr 12: 142, 2012. doi:10.1186/1471-2431-12-142.
28. Hunter CJ, Petrosyan M, Ford HR, Prasadarao NV. Enterobacter sakazakii: an emerging pathogen in infants and neonates. Surg Infect (Larchmt) 9: 533–539, 2008. doi:10.1089/sur.2008.006.
29. Jacobsson S, Jonsson L, Rank F, Rothman U. Studies on healing of Debrisan-treated wounds. Scand J Plast Reconstr Surg 10: 97–101, 1976. doi:10.3109/02844317609105196.
30. Jenke A, Ruf EM, Hoppe T, Heldmann M, Wirth S. Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy. Arch Dis Child Fetal Neonatal Ed 97: F217–F218, 2012. doi:10. 1136/archdischild-2011-300838.
31. Jones SE, Versalovic J. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol 9: 35, 2009. doi:10.1186/1471-2180-9-35.
32. Kleessen B, Bunke H, Tovar K, Noack J, Sawatzki G. Influence of two infant formulas and human milk on the development of the faecal flora in newborn infants. Acta Paediatr 84: 1347–1356, 1995. doi:10.1111/j.1651-2227.1995.tb13567.x.
33. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 38: 457–458, 2004. doi:10.1097/00005176-200404000-00017.
34. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115: 178–181, 2005. doi:10.1542/peds.2004-2137.
35. Liu Y, Fatheree NY, Dingle BM, Tran DQ, Rhoads JM. Lactobacillus reuteri DSM 17938 changes the frequency of Foxp3+ regulatory T cells in the intestine and mesenteric lymph node in experimental necrotizing enterocolitis. PLoS One 8: e56547, 2013. doi:10.1371/journal.pone.0056547.
36. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 299: G1087–G1096, 2010. doi:10.1152/ajpgi.00124.2010.
37. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-κB signaling in the intestine. Am J Physiol Gastrointest Liver Physiol 302: G608–G617, 2012. doi:10.1152/ajpgi.00266.2011.
38. Mackos AR, Eubank TD, Parry NM, Bailey MT. Probiotic Lactobacillus reuteri attenuates the stressor-enhanced severity of Citrobacter rodentium infection. Infect Immun 81: 3253–3263, 2013. doi:10.1128/IAI. 00278-13.
39. Mackos AR, Galley JD, Eubank TD, Easterling RS, Parry NM, Fox JG, Lyte M, Bailey MT. Social stress-enhanced severity of Citrobacter rodentium-induced colitis is CCL2-dependent and attenuated by probiotic Lactobacillus reuteri. Mucosal Immunol 9: 515–526, 2016. doi:10.1038/mi.2015.81.
40. Mai V, Young CM, Ukhanova M, Wang X, Sun Y, Casella G, Theriaque D, Li N, Sharma R, Hudak M, Neu J. Fecal microbiota in premature infants prior to necrotizing enterocolitis. PLoS One 6: e20647, 2011. doi:10.1371/journal.pone.0020647.
41. Molinaro F, Paschetta E, Cassader M, Gambino R, Musso G. Probiotics, prebiotics, energy balance, and obesity: mechanistic insights and therapeutic implications. Gastroenterol Clin North Am 41: 843–854, 2012. doi:10.1016/j.gtc.2012.08.009.
42. Morrow AL, Lagomarcino AJ, Schibler KR, Taft DH, Yu Z, Wang B, Altaye M, Wagner M, Gevers D, Ward DV, Kennedy MA, Huttenhower C, Newburg DS. Early microbial and metabolomic signatures predict later onset of necrotizing enterocolitis in preterm infants. Microbiome 1: 13, 2013. doi:10.1186/2049-2618-1-13.
43. Mshana SE, Gerwing L, Minde M, Hain T, Domann E, Lyamuya E, Chakraborty T, Imirzalioglu C. Outbreak of a novel Enterobacter sp. carrying blaCTX-M-15 in a neonatal unit of a tertiary care hospital in Tanzania. Int J Antimicrob Agents 38: 265–269, 2011. doi:10.1016/j. ijantimicag.2011.05.009.
44. Navarro JB, Mashburn-Warren L, Bakaletz LO, Bailey MT, Goodman SD. Enhanced probiotic potential of Lactobacillus reuteri when delivered as a biofilm on dextranomer microspheres that contain beneficial cargo. Front Microbiol 8: 489, 2017. doi:10.3389/fmicb.2017.00489.
45. Ohishi A, Takahashi S, Ito Y, Ohishi Y, Tsukamoto K, Nanba Y, Ito N, Kakiuchi S, Saitoh A, Morotomi M, Nakamura T. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr 156: 679–681, 2010. doi:10.1016/j.jpeds. 2009.11.041.
46. Ollech JE, Shen NT, Crawford CV, Ringel Y. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Best Pract Res Clin Gastroenterol 30: 111–118, 2016. doi:10.1016/j.bpg. 2016.01.002.
47. Olson JK, Rager TM, Navarro JB, Mashburn-Warren L, Goodman SD, Besner GE. Harvesting the benefits of biofilms: a novel probiotic delivery system for the prevention of necrotizing enterocolitis. J Pediatr Surg 51: 936–941, 2016. doi:10.1016/j.jpedsurg.2016.02.062.
48. Pammi M, Cope J, Tarr PI, Warner BB, Morrow AL, Mai V, Gregory KE, Kroll JS, McMurtry V, Ferris MJ, Engstrand L, Lilja HE, Hollister EB, Versalovic J, Neu J. Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: a systematic review and meta-analysis. Microbiome 5: 31, 2017. doi:10.1186/s40168-017-0248-8.
49. Rager TM, Olson JK, Zhou Y, Wang Y, Besner GE. Exosomes secreted from bone marrow-derived mesenchymal stem cells protect the intestines from experimental necrotizing enterocolitis. J Pediatr Surg 51: 942–947, 2016. doi:10.1016/j.jpedsurg.2016.02.061.
50. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 16: 658–672, 2003. doi:10.1128/CMR.16.4.658-672.2003.
51. Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr Issues Intest Microbiol 2: 43–53, 2001.
52. Salas-Jara MJ, Ilabaca A, Vega M, García A. Biofilm forming Lactobacillus: new challenges for the development of probiotics. Microorganisms 4: E35, 2016. doi:10.3390/microorganisms4030035.
53. Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, Sarna S, Valtonen V, Järvinen A. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35: 1155–1160, 2002. doi:10.1086/342912.
54. Schreck Bird A, Gregory PJ, Jalloh MA, Risoldi Cochrane Z, Hein DJ. Probiotics for the treatment of infantile colic: a systematic review. J Pharm Pract, 30: 366–374, 2017. doi:10.1177/0897190016634516.
55. Schreiber O, Petersson J, Phillipson M, Perry M, Roos S, Holm L. Lactobacillus reuteri prevents colitis by reducing P-selectin-associated leukocyte-and platelet-endothelial cell interactions. Am J Physiol Gastrointest Liver Physiol 296: G534–G542, 2009. doi:10.1152/ajpgi.90470. 2008.
56. Spinler JK, Sontakke A, Hollister EB, Venable SF, Oh PL, Balderas MA, Saulnier DM, Mistretta TA, Devaraj S, Walter J, Versalovic J, Highlander SK. From prediction to function using evolutionary genomics: human-specific ecotypes of Lactobacillus reuteri have diverse probiotic functions. Genome Biol Evol 6: 1772–1789, 2014. doi:10.1093/gbe/evu137.
57. Stenberg A, Läckgren G. A new bioimplant for the endoscopic treatment of vesicoureteral reflux: experimental and short-term clinical results. J Urol 154: 800–803, 1995. doi:10.1016/S0022-5347(01)67168-4.
58. Talarico TL, Dobrogosz WJ. Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri. Antimicrob Agents Chemother 33: 674–679, 1989. doi:10.1128/AAC.33.5.674.
59. Underwood MA, Arriola J, Gerber CW, Kaveti A, Kalanetra KM, Kananurak A, Bevins CL, Mills DA, Dvorak B. Bifidobacterium longum subsp. infantis in experimental necrotizing enterocolitis: alterations in inflammation, innate immune response, and the microbiota. Pediatr Res 76: 326–333, 2014. doi:10.1038/pr.2014.102.
60. Urbańska M, Szajewska H. The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence. Eur J Pediatr 173: 1327–1337, 2014. doi:10.1007/s00431-014-2328-0.
61. Valeur N, Engel P, Carbajal N, Connolly E, Ladefoged K. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol 70: 1176–1181, 2004. doi:10.1128/AEM.70.2.1176-1181.2004.
62. Walter J, Schwab C, Loach DM, Gänzle MG, Tannock GW. Gluco-syltransferase A (GtfA) and inulosucrase (Inu) of Lactobacillus reuteri TMW1.106 contribute to cell aggregation, in vitro biofilm formation, and colonization of the mouse gastrointestinal tract. Microbiology 154: 72–80, 2008. doi:10.1099/mic.0.2007/010637-0.
63. Wang Q, Dong J, Zhu Y. Probiotic supplement reduces risk of necrotizing enterocolitis and mortality in preterm very low-birth-weight infants: an updated meta-analysis of 20 randomized, controlled trials. J Pediatr Surg 47: 241–248, 2012. doi:10.1016/j.jpedsurg.2011.09.064.
64. Wang Y, Hoenig JD, Malin KJ, Qamar S, Petrof EO, Sun J, Antonopoulos DA, Chang EB, Claud EC. 16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. ISME J 3: 944–954, 2009. doi:10.1038/ismej.2009.37.
65. Ward DV, Scholz M, Zolfo M, Taft DH, Schibler KR, Tett A, Segata N, Morrow AL. Metagenomic sequencing with strain-level resolution implicates uropathogenic E. coli in necrotizing enterocolitis and mortality in preterm infants. Cell Reports 14: 2912–2924, 2016. doi:10.1016/j. celrep.2016.03.015.
66. Warner BB, Deych E, Zhou Y, Hall-Moore C, Weinstock GM, Soder-gren E, Shaikh N, Hoffmann JA, Linneman LA, Hamvas A, Khanna G, Rouggly-Nickless LC, Ndao IM, Shands BA, Escobedo M, Sullivan JE, Radmacher PG, Shannon WD, Tarr PI. Gut bacteria dysbiosis and necrotising enterocolitis in very low birthweight infants: a prospective case-control study. Lancet 387: 1928–1936, 2016. doi:10.1016/S0140-6736(16)00081-7.
67. Wasilewski A, Zielińska M, Storr M, Fichna J. Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease. Inflamm Bowel Dis 21: 1674–1682, 2015. doi:10.1097/MIB.0000000000000364.
68. Weng M, Ganguli K, Zhu W, Shi HN, Walker WA. Conditioned medium from Bifidobacteria infantis protects against Cronobacter saka-zakii-induced intestinal inflammation in newborn mice. Am J Physiol Gastrointest Liver Physiol 306: G779–G787, 2014. doi:10.1152/ajpgi. 00183.2013.
69. Weng M, Walker WA. The role of gut microbiota in programming the immune phenotype. J Dev Orig Health Dis 4: 203–214, 2013. doi:10. 1017/S2040174412000712.
70. Wu SF, Chiu HY, Chen AC, Lin HY, Lin HC, Caplan M. Efficacy of different probiotic combinations on death and necrotizing enterocolitis in a premature rat model. J Pediatr Gastroenterol Nutr 57: 23–28, 2013. doi:10.1097/MPG.0b013e3182929210.
71. Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 107: 56–59, 2015. doi:10.1159/000367985.